The medical device maker has completed more than 40 acquisitions in recent years, helping turn it into one of the state’s ...

Boston Scientific (NYSE: BSX) + today reported third-quarter results that came in ahead of the consensus forecast, raising its 2024 guidance again. The company’s CEO also said on its third ...

The company is one of the leading players in the interventional cardiology market with its coronary stent product offerings. Boston Scientific markets a broad portfolio of internally-developed and ...

Good morning and welcome to the Boston Scientific ... growth in TheraSphere. Cardiology delivered another exceptional quarter with sales growing 29%. Within Cardiology, Interventional Cardiology ...

The upcoming report from Boston Scientific (BSX ... prediction of analysts places 'Net Sales- Cardiovascular- Interventional Cardiology Therapies- Worldwide' at $623.44 million.

at 1 millimeter less than the perimeter-derived diameter,” Boston Scientific’s chief medical officer for interventional cardiology therapies, Janar Sathananthan, M.D., said in an interview.

Boston Scientific Corporation ... digit growth in TheraSphere. Cardiology delivered another exceptional quarter with sales ...

Derived prices are not provided by exchanges. They are derived by market makers in CFD OTC market and hence prices may not be accurate and may differ from the actual market price, meaning prices ...

Erica Denhoff / Icon Sportswire via Getty Images Boston Scientific shares fell Wednesday as its third-quarter profit missed estimates. The medical device maker's adjusted earnings per share and ...

Boston Scientific (NYSE: BSX) is scheduled to report its Q3 2024 results on Wednesday, October 23. We expect the company to report revenues and earnings slightly below the consensus estimates.